India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

Heart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with...

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previ...

Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies ...

The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the...

India's pharmaceutical market rebounded in November with 9.9% value growth and 3.1% volume growth. Key therapy areas like cardiac, gastroin...

"The respiratory market shows the normal seasonal trend for the anti-asthma and cough and cold segment," said Sheetal Sapale, VP, commercia...

Amongst the top 10 therapies that contribute to more than 90% of the Indian pharma market, price drove growth in the cardiac segment. The a...

India's cardiac and anti-diabetes drugs market has surged over threefold in the past decade, reaching ₹30,000 crore and ₹17,000 crore respe...

Sheetal Sapale, VP, commercial, Pharmarack, said four key therapy segments - cardiac, anti-infectives, gastro and respiratory - have driven...

The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastroi...

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...

Indian drug manufacturers are utilizing flagship products or "mother brands" to introduce new combinations and establish leadership in ther...

India's pharmaceutical market witnessed a robust 9% month-on-month growth in February, driven by strong performance in cardiology and anti-...

The Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. A...

According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...

Among the top therapies, cardiac, anti-infectives and neuro/central nervous system have shown a relatively stronger volume growth last mont...